TICKERNERD
Menu
BEAMBEAMHealthcare · Biotechnology

BEAM Stock Forecast: Beam Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$26
+1.53% on the day

The 15 Wall Street analysts covering Beam Therapeutics, Inc. hold a median 12-month price target of $47 — +81.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 1 Aug 2026 — in the upper half.

Market cap
$2.6B
Ticker Nerd rank
64 / 100
Median analyst target
$47
Analysts covering
15
Total return, dividends reinvested
1W
+3.4%
1M
−25.5%
YTD
−6.5%
1Y
+37.6%
From 52W high
−31.7%
From 52W low
+61.8%
$16
$38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BEAM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Beam Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
64 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
98
Revisions
80
Quality
73
Momentum
67
Value
61
Size
33
Volatility
31
Accruals
27
Issuance
18

Growth (98): Sales and profits are climbing, and climbing faster than before.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Beam Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

BEAM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BEAM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80Oct 25Jan 26Apr 26Jul 26BEAMHigh $80Median $47Low $26

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
13 Buy2 Hold0 Sell
Low $26Median $47High $80

The green dot is the last close — the median target sits +81.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 July 2026B of A SecuritiesReiteratesBuy$47
7 July 2026HC Wainwright & Co.ReiteratesBuy$80
13 May 2026BernsteinMaintainsOutperform—
26 Mar 2026CitigroupMaintainsBuy—
25 Feb 2026RBC CapitalMaintainsSector Perform—
25 Feb 2026WedbushMaintainsOutperform—
20 Feb 2026Canaccord GenuityInitiatesBuy—
21 Jan 2026BernsteinMaintainsOutperform—
7 Jan 2026UBSInitiatesNeutral—
24 Nov 2025Evercore ISI GroupInitiatesOutperform—
10 Oct 2025HC Wainwright & Co.ReiteratesBuy—
9 Oct 2025JP MorganMaintainsOverweight—
15 Sept 2025HC Wainwright & Co.ReiteratesBuy—
6 Aug 2025BarclaysMaintainsEqual-Weight—
7 May 2025BarclaysMaintainsEqual-Weight—
7 May 2025GuggenheimMaintainsBuy—
7 May 2025Wells FargoMaintainsOverweight—
7 Apr 2025HC Wainwright & Co.ReiteratesBuy—
28 Mar 2025B of A SecuritiesUpgradeBuy—
12 Mar 2025Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

BEAM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
7
Analysts cutting
5
Fundamentals

Beam Therapeutics, Inc. (BEAM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−31.5×

Cheaper than 97% of US stocks

Price / sales
16.0×

Cheaper than 10% of US stocks

Price / book
2.2×

Cheaper than 43% of US stocks

EV / EBITDA
−4.5×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
324.9%

Higher than 97% of US stocks

Earnings growth (YoY)
324.9%

Higher than 94% of US stocks

Gross margin
—
Operating margin
−337.8%

Higher than 9% of US stocks

Net margin
−40.2%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−5.8%

Higher than 39% of US stocks

Return on assets
−15.8%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BEAM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BEAMBeam Therapeutics, Inc.$2.6B
64
ATAIAtai Beckley, Inc.$2.6B
35
TRVITrevi Therapeutics, Inc.$2.6B
53
TARSTarsus Pharmaceuticals, Inc.$2.5B
79
IMNMImmunome, Inc.$2.5B
49
KODKodiak Sciences, Inc.$2.5B
55
RAREUltragenyx Pharmaceutical, Inc.$2.5B
38
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BEAM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest BEAM news & analysis

Beam Therapeutics: A Valuation With Upside Left

Seeking Alpha · 3 Aug 2026positive

Seeking Alpha published a valuation analysis of Beam Therapeutics, citing its $2.64B market cap and a gene-editing pipeline covering hematology and liver-targeted diseases. The piece highlights lead programs Risto-cel, BEAM-302, and BEAM-301, as well as the company's $1.2B liquidity providing a cash runway into 2029, supplemented by collaboration revenue from Eli Lilly and Pfizer.

Why it matters — BEAM watchers would note the article's view that the company's pipeline shows competitive efficacy and safety with ample funding, which bears on its longer-term commercial potential.

FAQ

Frequently asked questions about BEAM stock

What is the BEAM stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Beam Therapeutics, Inc. have a median 12-month price target of $47, with estimates ranging from $26 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BEAM stock a buy right now?

Of the 15 analysts covering Beam Therapeutics, Inc., 13 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Beam Therapeutics, Inc. 64 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BEAM?

As at 1 Aug 2026, Beam Therapeutics, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).

Will BEAM stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +81.4% from the last close, and Ticker Nerd's factor model ranks Beam Therapeutics, Inc. 64 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BEAM stock forecast for 2030?

No analyst covering Beam Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BEAM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $80 over the next 12 months.

How has BEAM stock performed over the past year?

Beam Therapeutics, Inc. returned +37.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Beam Therapeutics, Inc. do?

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using base editing technology.

What is the latest news on BEAM?

The most recent item we track (Seeking Alpha, 3 Aug 2026): "Beam Therapeutics: A Valuation With Upside Left". Seeking Alpha published a valuation analysis of Beam Therapeutics, citing its $2.64B market cap and a gene-editing pipeline covering hematology and liver-targeted diseases. The piece highlights lead programs Risto-cel, BEAM-302, and BEAM-301, as well as the company's $1.2B liquidity providing a cash runway into 2029, supplemented by collaboration revenue from Eli Lilly and Pfizer.

Company

About Beam Therapeutics, Inc.

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using base editing technology. The company designs therapies that aim to make targeted, single-base changes in DNA or RNA, with the goal of precisely correcting disease-causing mutations at the molecular level. Beam Therapeutics Inc. concentrates on serious conditions across areas such as hematology, liver and metabolic disorders, oncology, and genetic diseases, advancing a pipeline that includes programs like BEAM-101, BEAM-201, BEAM-301, and BEAM-302, as well as its ESCAPE platform for engineered stem cell therapies. Its business model centers on proprietary editing platforms, internal drug discovery, and strategic collaborations with larger pharmaceutical and biotechnology companies to co-develop or outlicense selected programs. Founded in 2017 and headquartered in Cambridge, Massachusetts, Beam Therapeutics Inc. plays a specialized role in the health technology and biotechnology sectors by providing tools and candidate therapies that support the broader shift toward highly targeted, mechanism-based treatments.

CEO Mr. John M. Evans M.B.A. · 522 employees · United States · https://beamtx.com